Freedom of Information request (FOI 22/860)
Published 17 January 2024
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-29-august-2022/freedom-of-information-request-foi-22860
FOI 22-860
30th August 2022
Dear
Thank you for your email refining the data requested and provided as part of FOI 22/610. You have requested all reports and data held supporting the efficacy and safety of Citalopram (SSRIs) in people diagnosed with anxiety under the Freedom of Information Act .
As the table provided in FOI 22/610 outlines, citalopram is not specifically licensed for the treatment of anxiety and therefore data supporting the efficacy of citalopram for use in anxiety have not been submitted for licensing assessment and therefore MHRA do not hold these data. Citalopram is licensed for use in Panic Disorder which is classified in the psychiatric diagnostic statistical manual (DSM v5) as an Anxiety Disorder and therefore we are able to provide you with a summary of the Yellow card reports received in the indication of Panic Disorder as of 23/08/2022 in table 1 below. We have further divided the number of reports by the age cut off you requested in the previous FOI request of 30 years.
Table 1. Number of Yellow Card received associated with Citalopram use in Patients with Panic Disorder.
| CITALOPRAM | |
|---|---|
| Data category | Number of reports |
| Indication Panic disorder- age not stated | 19 |
| Indication Panic disorder and patient age<30 years | 7 |
| Indication Panic disorder and patient age ≥30 years | 10 |
I hope the information provided is helpful; however, if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Please remember to quote the reference number above in any future communications.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division